Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
The overall objective of the proposed study is to determine if lofexidine (LFX) as an adjunct
to buprenorphine (BUP) treatment improves symptoms of both opioid use disorder (OUD) and
Post-Traumatic Stress Disorder (PTSD). Other study objectives are to compare the safety,
tolerability, and efficacy of BUP treatment alone, to BUP treatment with adjunct LFX, on
measures of OUD and PTSD symptoms in Veterans with both prognosis .
Phase:
Phase 2
Details
Lead Sponsor:
Pharmacotherapies for Alcohol and Substance Abuse Consortium
Collaborators:
Michael Debakey Veterans Affairs Medical Center Michael E. DeBakey VA Medical Center RTI International United States Department of Defense US WorldMeds LLC